Home Biosimilar Antibodies Immunology & Inflammation Immunology & Inflammation related Tiragolumab (anti-TIGIT)
For research use only. Not for use in humans.

Tiragolumab (anti-TIGIT)

Synonyms: VSTM3， VSIG9

Tiragolumab (anti-TIGIT) (RG6058, MTIG7192A) is a humanized IgG1/kappa monoclonal antibody that binds TIGIT to prevent its interaction with its ligand PVR (CD155).

Tiragolumab (anti-TIGIT)

Click to purchase the isotype control of Tiragolumab (anti-TIGIT)

9 Citations

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: Purity: 99.79% Protein concentration: 6.7mg/ml Endotoxin Level: <1 EU/mg
99.79

Specificity

Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Tiragolumab (anti-TIGIT) (RG6058, MTIG7192A) is a humanized IgG1/kappa monoclonal antibody that binds TIGIT to prevent its interaction with its ligand PVR (CD155).
References

Product Details

CAS No. 1918185-84-8
Molecular Weight 149 KDa
Isotype Human IgG1, κ
Source CHO cells
Purification PBS Buffer, PH 7.4
Sterility 0.2 μM filtered
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05862285 RECRUITING Drug: Ipatasertib|Drug: Tiragolumab|Drug: Atezolizumab|Drug: Cancer Hoffmann-La Roche 2023-06-01 PHASE3
NCT04929223 RECRUITING Drug: Inavolisib|Drug: Bevacizumab|Drug: Cetuximab|Drug: Ate Metastatic Colorectal Cancer Hoffmann-La Roche 2021-10-22 PHASE1
NCT05286801 ACTIVE_NOT_RECRUITING Atypical Teratoid/Rhabdoid Tumor; Epithelioid Sarcoma; Kidney Medullary Carcinoma; Malignant Solid Neoplasm; Poorly Differentiated Chordoma; Recurrent Atypical Teratoid/Rhabdoid Tumor; Recurrent Chordoma; Recurrent Epithelioid Sarcoma; Recurrent Kidney Medullary Carcinoma; Recurrent Malignant Solid Neoplasm; Recurrent Rhabdoid Tumor; Refractory Atypical Teratoid/Rhabdoid Tumor; Refractory Chordoma; Refractory Epithelioid Sarcoma; Refractory Kidney Medullary Carcinoma; Refractory Malignant Solid Neoplasm; Refractory Rhabdoid Tumor; Rhabdoid Tumor National Cancer Institute (NCI) 2022-11-17 PHASE1; PHASE2
NCT05394337 RECRUITING Drug: Atezolizumab|Drug: Tiragolumab Metastatic Malignancy M.D. Anderson Cancer Center 2023-02-23 PHASE1; PHASE2
NCT06331598 WITHDRAWN Drug: Atezolizumab|Drug: Tiragolumab Solid Tumors Hoffmann-La Roche 2024-11-30 PHASE2
NCT06760481 ACTIVE_NOT_RECRUITING Drug: Tiragolumab|Drug: Atezolizumab Advanced Solid Malignancies M.D. Anderson Cancer Center 2025-04-13 PHASE1

(data from https://clinicaltrials.gov, updated on 2026-09-02)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.